Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant phase II study of nivolumab + abemaciclib or palbociclib + anastrozole in ER-positive/HER2-negative breast cancer
2019-001334-34Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer and Estrogen receptor-positive HER2-negative breast cancer (ER+/HER2-) comparing Nivolumab + abemaciclib + anastrozole with Palbociclib + anastrozole (2 arms). Primary endpoint: Dose limiting toxicity. Started Sep 2019; status: terminated.
02
Drugs
03
Conditions
breast cancerEstrogen receptor-positive HER2-negative breast cancer (ER+/HER2-)
Beyond the preview
Go deeper on 2019-001334-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001334-34.